Universal prenatal hepatitis C virus (HCV) screening was found to be cost-effective and improved health outcomes in women diagnosed with HCV infection and identification of HCV exposure in neonates, according to a study published in Obstetrics & Gynecology. A research team used a stochastic microsimulation model to analyze the health outcomes and cost-effectiveness of universal…
Topline data from the Phase 3 STELLAR-4 trial showed that selonsertib, an investigational treatment for patients with compensated cirrhosis due to nonalcoholic steatohepatitis (NASH), was not associated with a significant improvement in fibrosis without worsening of NASH. The safety and efficacy of selonsertib, an oral inhibitor of apoptosis signal-regulating kinase 1 (ASK1), was evaluated in a double-blind,…
The Advisory Committee on Immunization Practices Hepatitis Vaccines Work Group has updated recommendations for hepatitis A vaccination for PEP and PrEP.
Those with HCV genotype 1 with recent injection drug use and/or current opioid substitution therapy, paritaprevir/ritonavir, ombitasvir, and dasabuvir with/without ribavirin is effective.
Patients with chronic HCV undergoing short-term glecaprevir and pibrentasvir treatment show improved cardiovascular and metabolic extrahepatic manifestations.
The approval was based on data from the KEYNOTE-224 study, a single-arm trial in patients with HCC who had disease progression on or after sorafenib or were intolerant to sorafenib; had measurable disease; and Child-Pugh class A liver impairment.
Adherence to the American Association for the Study of Liver Diseases criteria for evaluation and treatment of chronic HBV infection was found to be poor in all practice settings assessed.
